Medical cannabinoid products are widely used in Canada to treat medical symptoms of all kinds, and gastrointestinal (GI) symptoms are among the most commonly cited reasons for use. Cannabis is also widely used recreationally, and legalization of recreational use has occurred in Canada. Cannabis can be beneficial for individuals taking opioid medications for abdominal pain. Research shows that cannabis helps patients cut down on or eliminate their need for opioids and provides treatment with fewer side effects. Cannabis also helps individuals who have difficulty eating enough by increasing appetite and can help reduce diarrhoea and nausea.
Key factors supporting the growth are rise in prevalence of cannabis intake for GI disease. The need to develop better product delivery systems and sustainable product strains. This need has, in turn, led to many companies coming up with R&D, which extensively investigates several genetic improvement strategies for cannabis. While the public opinion of cannabis has gone through many shifts, public interest in Canada has continued to grow in recent years. With the legalization of cannabis in Canada and more research, people are getting a deeper understanding of how cannabis works in humans.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us at info@insights10.com
Rising prevalence of breast cancer pertaining to factors such as prolonged exposure to endogenous oestrogens, early menarche, late age at first childbirth and late menopause will be a high impact rendering factor for the industry growth. Increasing technological advances in cancer biology and launch of several diagnostic and screening programs worldwide should drive the business size. Growing adoption of therapeutics owing to factors such as blocking estrogenic from binding to tumour cells, risk of distant reappearance, lowering jeopardy of reappearance in the breast that had tumour and reducing risk of developing disease in another breast will propel the industry growth.
Growing awareness regarding breast cancer, rising shift towards adoption of western lifestyle, short breast-feeding timeframe and rising prevalence of obesity in women after menopause will drive the industry size. Increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT) and oral birth control pills resulting in increased levels of oestrogen will boost the business size over the forecast period. Growing exposure to certain carcinogens and endocrine disruptors, for example in the workplace, working night shifts results in increased risk are surging up the U.S. market
Prohibitive cost associated with the use of breast cancer therapeutics may hamper the industry growth. Increasing cost of early and late-stage disease therapy, continuing care on a per-unit time basis, accounting for the major share of lifetime cost owing to relatively extended survival of breast cancer patients may further restrain the business growth
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us at info@insights10.com
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts an individual ability to focus, self-control, and perform other skills important in daily life. ADHD is caused due to biochemical, connectivity, and the structural difference in the mind. Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) mostly advances over a period and vary according to the type of causing factor and according to the age group of the person. The common symptoms in patient population are trouble at work, low self-esteem and substance abuse or ADHD, low-stress tolerance level, mood swings, and many more. Further, based on symptoms, ADHD is classified into three key categories including the predominantly inattentive, predominantly hyperactive-impulsive, and combined type. ADHD is diagnosed using a comprehensive evaluation of the patient’s mental and behavioral condition. Various treatment options are pharmacological treatment, educational interventions & other behavioral therapies, and EEG biofeedback therapies, physicians could reduce the disorder symptoms and their effects on the individual health.
The global attention deficit hyperactivity disorder (ADHD) market is expected to grow with increasing pharmaceutical R&D spending, growing healthcare expenditure, accelerating economic growth, unmet treatment needs, and mounting occurrence of ADHD. Key trends and developments of this market include progressing drugs under pipeline, high demand for dual therapy, and rising preference for EEG biofeedback therapy. However, there are some factors that can hinder the growth of the market including Medical complications of existing drug therapies, high domination of the generic pharmaceutical market, and strict government protocols
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us at info@insights10.com
Medical Marijuana Market Size, Share, Trends and Growth Analysis Research, 20...Signitech
The global medical marijuana market size was valued at USD 11.4 billion in 2015 and is projected to grow with CAGR of 17.1% during the forecast period.
The global gene therapy market size was valued at USD 536.43 million in 2018 and is expected to register a CAGR of 33.9% assuming the projected successful commercialization of some of the key therapeutics, that are planned over the forecast period.
Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico
DELOITTE: 2017 Global Health Sciences Outlook Report - A global perspective on the healthcare industry and its strategic sectors. Deloitte efficiently delivers an uncomplicated but in-depth look at worldwide healthcare. Rising demand and associated spending are being fueled by an aging population; the growing prevalence of chronic diseases and comorbidities; development of costly clinical innovations; increasing patient awareness, knowledge, and expectations; and continued economic uncertainty despite regional pockets of recovery are just a few of the key issues and trends impacting the global health care sector.
Connect with me at LinkedIn and Twitter, visit my healthcare website -an industry resource since 2004...
Twitter: @johngbaresky
LinkedIn: https://www.linkedin.com/in/johngbaresky
My website: www.healthcaremedicalpharmaceuticaldirectory.com
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
Epigenetics Diagnostic Market Size, Share, Growth, Trends and Forecast Report...Signitech
The global epigenetics diagnostic market size was valued at USD 5.5 billion in 2018 and is estimated to register a CAGR of 18.8% over the forecast period. Increasing prevalence of cancer and other chronic diseases and growing geriatric population are some of the key factors expected to drive the market.
Rising prevalence of breast cancer pertaining to factors such as prolonged exposure to endogenous oestrogens, early menarche, late age at first childbirth and late menopause will be a high impact rendering factor for the industry growth. Increasing technological advances in cancer biology and launch of several diagnostic and screening programs worldwide should drive the business size. Growing adoption of therapeutics owing to factors such as blocking estrogenic from binding to tumour cells, risk of distant reappearance, lowering jeopardy of reappearance in the breast that had tumour and reducing risk of developing disease in another breast will propel the industry growth.
Growing awareness regarding breast cancer, rising shift towards adoption of western lifestyle, short breast-feeding timeframe and rising prevalence of obesity in women after menopause will drive the industry size. Increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT) and oral birth control pills resulting in increased levels of oestrogen will boost the business size over the forecast period. Growing exposure to certain carcinogens and endocrine disruptors, for example in the workplace, working night shifts results in increased risk are surging up the U.S. market
Prohibitive cost associated with the use of breast cancer therapeutics may hamper the industry growth. Increasing cost of early and late-stage disease therapy, continuing care on a per-unit time basis, accounting for the major share of lifetime cost owing to relatively extended survival of breast cancer patients may further restrain the business growth
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us at info@insights10.com
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts an individual ability to focus, self-control, and perform other skills important in daily life. ADHD is caused due to biochemical, connectivity, and the structural difference in the mind. Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) mostly advances over a period and vary according to the type of causing factor and according to the age group of the person. The common symptoms in patient population are trouble at work, low self-esteem and substance abuse or ADHD, low-stress tolerance level, mood swings, and many more. Further, based on symptoms, ADHD is classified into three key categories including the predominantly inattentive, predominantly hyperactive-impulsive, and combined type. ADHD is diagnosed using a comprehensive evaluation of the patient’s mental and behavioral condition. Various treatment options are pharmacological treatment, educational interventions & other behavioral therapies, and EEG biofeedback therapies, physicians could reduce the disorder symptoms and their effects on the individual health.
The global attention deficit hyperactivity disorder (ADHD) market is expected to grow with increasing pharmaceutical R&D spending, growing healthcare expenditure, accelerating economic growth, unmet treatment needs, and mounting occurrence of ADHD. Key trends and developments of this market include progressing drugs under pipeline, high demand for dual therapy, and rising preference for EEG biofeedback therapy. However, there are some factors that can hinder the growth of the market including Medical complications of existing drug therapies, high domination of the generic pharmaceutical market, and strict government protocols
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us at info@insights10.com
Medical Marijuana Market Size, Share, Trends and Growth Analysis Research, 20...Signitech
The global medical marijuana market size was valued at USD 11.4 billion in 2015 and is projected to grow with CAGR of 17.1% during the forecast period.
The global gene therapy market size was valued at USD 536.43 million in 2018 and is expected to register a CAGR of 33.9% assuming the projected successful commercialization of some of the key therapeutics, that are planned over the forecast period.
Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico
DELOITTE: 2017 Global Health Sciences Outlook Report - A global perspective on the healthcare industry and its strategic sectors. Deloitte efficiently delivers an uncomplicated but in-depth look at worldwide healthcare. Rising demand and associated spending are being fueled by an aging population; the growing prevalence of chronic diseases and comorbidities; development of costly clinical innovations; increasing patient awareness, knowledge, and expectations; and continued economic uncertainty despite regional pockets of recovery are just a few of the key issues and trends impacting the global health care sector.
Connect with me at LinkedIn and Twitter, visit my healthcare website -an industry resource since 2004...
Twitter: @johngbaresky
LinkedIn: https://www.linkedin.com/in/johngbaresky
My website: www.healthcaremedicalpharmaceuticaldirectory.com
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
Epigenetics Diagnostic Market Size, Share, Growth, Trends and Forecast Report...Signitech
The global epigenetics diagnostic market size was valued at USD 5.5 billion in 2018 and is estimated to register a CAGR of 18.8% over the forecast period. Increasing prevalence of cancer and other chronic diseases and growing geriatric population are some of the key factors expected to drive the market.
Japan generics drug market outlook 2020Rajesh Sarma
“Japan Generics Drug Market Outlook 2020” Report Highlights:
Introduction to Japanese Generic Drug Market
Attractiveness of Japanese Generic Market
Super Generics in Japan
Japan Healthcare System & Generic Drugs
Different Parameters for Generic & Branded Drugs
Comparison of Generic Drugs in US & Japan
Japan Generics Drug Market Analysis
Japan Generics Drug Market Future Prospects
According to www.techsciresearch.com latest Report- Global oncology drugs market is projected to grow at a brisk rate over the forecast period owing to widespread prevalence of cancer, globally.
Report URL- https://www.techsciresearch.com/report/oncology-drugs-market/4689.html
Biological Safety Testing Market Size, Product Analysis and Applications, 201...Signitech
The global biological safety testing market size was valued at USD 2.20 billion in 2016 and is anticipated to exhibit a CAGR of 12.2% during the forecast period.
Trends in Oncology Pharmaceuticals Business DevelopmentTim Opler
This presentation provides an overview of the evolving marketplace for oncology transactions and is a summary of discussion materials shared by Torreya at the Sachs Conference on September 26, 2019 in Basel, Switzerland.
Medicines outlook through_2016_report
source of info:
http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf
The global pharmaceutical drugs market was valued around $935 billion in 2017. North America was the largest region in the pharmaceutical drugs market in 2017, accounting for around 37% of the total market.
Read Report
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report-2018
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Chemotherapy Market Size, Share & Forecast | TechSci Research TechSci Research
According to www.techsciresearch.com latest report- Global Chemotherapy Market By Drugs (Alone, Combination), By Type (Alkylating Agents, Nitrosoureas, Antimetabolites, Anti-tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Corticosteroids, Others), By Indication (Leukaemia, Lymphoma, Hodgkin Disease, Multiple Myeloma, Sarcoma, Bone Marrow Disease, Immune System Disorder), By Route of Administration (Intravenous, Orally, Transdermal, Intraperitoneal, Intrapleural, Intrathecal, Intravesical, Others), By End-User (Hospitals, Specialty Center, Others), By Region, Forecast & Opportunities, 2025.
Report URL- https://www.techsciresearch.com/report/chemotherapy-market/4735.html
How is drug spending affected in the year 2017Steve Martin
As per the reports published in American Journal of Health-System Pharmacy (AJHP) in the year 2016, national trends in prescription drug expenditures were projected to increase by 6 to 8% in 2017 across all healthcare settings.
Global Antidepressant Drugs Market: Opportunities and Forecasts (2018-2023) Matloob Hasan
Globally, the market for antidepressant drugs mask has been growing at a swift pace on the back of rising prevalence mental disorders, rising healthcare awareness and rising disposable incomes. Apart from these factors, rising healthcare facilities, increasing number of psychiatrist as well as surging number of hospital and clinics and burgeoning growth in Asia Pacific market is impelling growth in the market.
The global antipsychotic drug market size is expected to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increase in incidences of psychotic disorders such as hallucinations, schizophrenia, bipolar disorder, delusions, and severe depression.
Canada Cannabis for GI Disease Market Analysis Sample ReportInsights10
The legalization of medical cannabis in Canada has resulted in the growth of Canada's cannabis for GI diseases market. Cannabis can be used to treat irritable bowel disease, inflammatory bowel diseases, and colitis. The market is segmented by application and by product type. To get a detailed report, contact us at - info@insights10.com
The Digital Health Market size in Canada was valued at more than USD 4.77 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of xx% from 2019 to 2028.
Provider and patient-centric solutions are dominating Canada’s digital health sector. But this year, the spotlight on a new segment: life science R&D, which has helped drive the development of diagnostics, vaccines, and treatments against the Covid-19 virus. Additionally, factors like demographic changes, waiting time, increasing burden of chronic diseases, outcome-based care, and other pressing industry challenges are compelling the Canadian healthcare system to deliver more with less. Technology adoption and spending trends, including the role of digital technologies in providing care in Canada, innovation in healthcare; driven by start-ups, changes in procurement processes, and evolution of transformative technologies such as analytics, mobility, IoT, remote, 3D, and augmented reality that is changing the Canadian healthcare market.
Market Drivers
Increasing cases of obesity, high prevalence of chronic diseases such as Diabetes, Cardiovascular, growing need for remote patient monitoring services, and increasing patient engagement and connectivity owing to high adoption of digital health technology are the major factors promoting the market growth.
The increasing awareness and growing adoption of advanced technologies like mHealth and telemedicine by the Canadian population are expected to boost digital health platforms. Additionally, many companies are entering into a digital pace focused on providing accessibility, quality, efficient treatment, and cost-effectiveness solution to Canadian patients.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
Canada’s Telemedicine market size stood at around USD XX.X billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Integrating healthcare with advanced technologies like IoT, and data analytics has increased the growth opportunities of the telemedicine market in Canada. Also, the emergence of home care devices and social platforms has improved communication between consumers and professionals for transferring information and physiological data, home care devices can track the health status of patients and will regularly update the data to professionals leading to rising demand for these devices. Besides, improved use of technology in healthcare conveyance and a lack of physicians in rural areas are foreseen to offer a new prospect for most of the telemedicine market.
Driving Factors
High incidences of chronic diseases, rising healthcare costs, technological innovations, an increase in the aging population, and rising awareness regarding remote patient monitoring are the major driving factors for the Canadian Telemedicine Market. According to the Canadian Attitudes on Healthcare and Telemedicine Report, 70% of Canadians believe virtual care represents the future. The research was sponsored by Canadian virtual healthcare leader Dialogue. In Canada, 46% say it would take more than 4 days to see a healthcare professional for a minor health concern and 22% say it would take more than a week. With the advent of advanced technologies such as machine learning, artificial intelligence, the Internet of Things (IoT), virtual hospitals, and telehealth apps, the adoption of telemedicine is increasing rapidly.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
The China Antiepileptic Drug market size stood at around USD XX billion in 2019 and is projected to reach USD 1.16 billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The prevalence of epilepsy in China is 7%, and the prevalence of active epilepsy is 4.6%. In addition, there is a large gap in the treatment of epilepsy, which is about 63%. Based on this, it is estimated that the current epilepsy number of patients is more than 9 million, of which more than 6.4 million are patients with active epilepsy.
Market Drivers
Increasing incidence of neurological disorder and rising geriatric population are some factors driving the growth of Antiepileptic drugs market. Increasing advancement of drug modification and increasing number of available Antiepileptic drugs are some factors driving the growth of the market. Moreover, advancement in drugs provide small effects on liver metabolism that converts into a lower rate of side effects further contributing to the growth of Antiepileptic Drugs Market. Active government support and Investments are expediting the market growth. The R&D is now focused on the development of target specific drugs.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
Canada Over The Counter (OTC) Drugs Market Analysis Report 2022 to 2030Insights10
Over the Counter (OTC) drugs market in Canada is very fragmented, and the market size is expected to increase from $13.6 Bn in 2022 to $23.6 Bn in 2030, with a CAGR of 7.1%. The Canada OTC industry analysis by Insights10 recognizes the increasing approval rates and the switch from prescription drugs to OTC drugs as major market drivers. The OTC market in Canada is segmented by category and by distribution channels. Pfizer, GlaxoSmithKline, and Boiron SA are some of the leading players in the OTC market.
Japan generics drug market outlook 2020Rajesh Sarma
“Japan Generics Drug Market Outlook 2020” Report Highlights:
Introduction to Japanese Generic Drug Market
Attractiveness of Japanese Generic Market
Super Generics in Japan
Japan Healthcare System & Generic Drugs
Different Parameters for Generic & Branded Drugs
Comparison of Generic Drugs in US & Japan
Japan Generics Drug Market Analysis
Japan Generics Drug Market Future Prospects
According to www.techsciresearch.com latest Report- Global oncology drugs market is projected to grow at a brisk rate over the forecast period owing to widespread prevalence of cancer, globally.
Report URL- https://www.techsciresearch.com/report/oncology-drugs-market/4689.html
Biological Safety Testing Market Size, Product Analysis and Applications, 201...Signitech
The global biological safety testing market size was valued at USD 2.20 billion in 2016 and is anticipated to exhibit a CAGR of 12.2% during the forecast period.
Trends in Oncology Pharmaceuticals Business DevelopmentTim Opler
This presentation provides an overview of the evolving marketplace for oncology transactions and is a summary of discussion materials shared by Torreya at the Sachs Conference on September 26, 2019 in Basel, Switzerland.
Medicines outlook through_2016_report
source of info:
http://www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/Global%20Use%20of%20Meds%202011/Medicines_Outlook_Through_2016_Report.pdf
The global pharmaceutical drugs market was valued around $935 billion in 2017. North America was the largest region in the pharmaceutical drugs market in 2017, accounting for around 37% of the total market.
Read Report
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-global-market-report-2018
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Chemotherapy Market Size, Share & Forecast | TechSci Research TechSci Research
According to www.techsciresearch.com latest report- Global Chemotherapy Market By Drugs (Alone, Combination), By Type (Alkylating Agents, Nitrosoureas, Antimetabolites, Anti-tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Corticosteroids, Others), By Indication (Leukaemia, Lymphoma, Hodgkin Disease, Multiple Myeloma, Sarcoma, Bone Marrow Disease, Immune System Disorder), By Route of Administration (Intravenous, Orally, Transdermal, Intraperitoneal, Intrapleural, Intrathecal, Intravesical, Others), By End-User (Hospitals, Specialty Center, Others), By Region, Forecast & Opportunities, 2025.
Report URL- https://www.techsciresearch.com/report/chemotherapy-market/4735.html
How is drug spending affected in the year 2017Steve Martin
As per the reports published in American Journal of Health-System Pharmacy (AJHP) in the year 2016, national trends in prescription drug expenditures were projected to increase by 6 to 8% in 2017 across all healthcare settings.
Global Antidepressant Drugs Market: Opportunities and Forecasts (2018-2023) Matloob Hasan
Globally, the market for antidepressant drugs mask has been growing at a swift pace on the back of rising prevalence mental disorders, rising healthcare awareness and rising disposable incomes. Apart from these factors, rising healthcare facilities, increasing number of psychiatrist as well as surging number of hospital and clinics and burgeoning growth in Asia Pacific market is impelling growth in the market.
The global antipsychotic drug market size is expected to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increase in incidences of psychotic disorders such as hallucinations, schizophrenia, bipolar disorder, delusions, and severe depression.
Canada Cannabis for GI Disease Market Analysis Sample ReportInsights10
The legalization of medical cannabis in Canada has resulted in the growth of Canada's cannabis for GI diseases market. Cannabis can be used to treat irritable bowel disease, inflammatory bowel diseases, and colitis. The market is segmented by application and by product type. To get a detailed report, contact us at - info@insights10.com
The Digital Health Market size in Canada was valued at more than USD 4.77 billion in 2019 and is expected to expand at a compound annual growth rate (CAGR) of xx% from 2019 to 2028.
Provider and patient-centric solutions are dominating Canada’s digital health sector. But this year, the spotlight on a new segment: life science R&D, which has helped drive the development of diagnostics, vaccines, and treatments against the Covid-19 virus. Additionally, factors like demographic changes, waiting time, increasing burden of chronic diseases, outcome-based care, and other pressing industry challenges are compelling the Canadian healthcare system to deliver more with less. Technology adoption and spending trends, including the role of digital technologies in providing care in Canada, innovation in healthcare; driven by start-ups, changes in procurement processes, and evolution of transformative technologies such as analytics, mobility, IoT, remote, 3D, and augmented reality that is changing the Canadian healthcare market.
Market Drivers
Increasing cases of obesity, high prevalence of chronic diseases such as Diabetes, Cardiovascular, growing need for remote patient monitoring services, and increasing patient engagement and connectivity owing to high adoption of digital health technology are the major factors promoting the market growth.
The increasing awareness and growing adoption of advanced technologies like mHealth and telemedicine by the Canadian population are expected to boost digital health platforms. Additionally, many companies are entering into a digital pace focused on providing accessibility, quality, efficient treatment, and cost-effectiveness solution to Canadian patients.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
Canada’s Telemedicine market size stood at around USD XX.X billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Integrating healthcare with advanced technologies like IoT, and data analytics has increased the growth opportunities of the telemedicine market in Canada. Also, the emergence of home care devices and social platforms has improved communication between consumers and professionals for transferring information and physiological data, home care devices can track the health status of patients and will regularly update the data to professionals leading to rising demand for these devices. Besides, improved use of technology in healthcare conveyance and a lack of physicians in rural areas are foreseen to offer a new prospect for most of the telemedicine market.
Driving Factors
High incidences of chronic diseases, rising healthcare costs, technological innovations, an increase in the aging population, and rising awareness regarding remote patient monitoring are the major driving factors for the Canadian Telemedicine Market. According to the Canadian Attitudes on Healthcare and Telemedicine Report, 70% of Canadians believe virtual care represents the future. The research was sponsored by Canadian virtual healthcare leader Dialogue. In Canada, 46% say it would take more than 4 days to see a healthcare professional for a minor health concern and 22% say it would take more than a week. With the advent of advanced technologies such as machine learning, artificial intelligence, the Internet of Things (IoT), virtual hospitals, and telehealth apps, the adoption of telemedicine is increasing rapidly.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
The China Antiepileptic Drug market size stood at around USD XX billion in 2019 and is projected to reach USD 1.16 billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The prevalence of epilepsy in China is 7%, and the prevalence of active epilepsy is 4.6%. In addition, there is a large gap in the treatment of epilepsy, which is about 63%. Based on this, it is estimated that the current epilepsy number of patients is more than 9 million, of which more than 6.4 million are patients with active epilepsy.
Market Drivers
Increasing incidence of neurological disorder and rising geriatric population are some factors driving the growth of Antiepileptic drugs market. Increasing advancement of drug modification and increasing number of available Antiepileptic drugs are some factors driving the growth of the market. Moreover, advancement in drugs provide small effects on liver metabolism that converts into a lower rate of side effects further contributing to the growth of Antiepileptic Drugs Market. Active government support and Investments are expediting the market growth. The R&D is now focused on the development of target specific drugs.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
Canada Over The Counter (OTC) Drugs Market Analysis Report 2022 to 2030Insights10
Over the Counter (OTC) drugs market in Canada is very fragmented, and the market size is expected to increase from $13.6 Bn in 2022 to $23.6 Bn in 2030, with a CAGR of 7.1%. The Canada OTC industry analysis by Insights10 recognizes the increasing approval rates and the switch from prescription drugs to OTC drugs as major market drivers. The OTC market in Canada is segmented by category and by distribution channels. Pfizer, GlaxoSmithKline, and Boiron SA are some of the leading players in the OTC market.
Canada's clinical diagnostics is expected to witness significant growth from $3.9 Bn in 2022 to $4.9 Bn in 2030 with a CAGR of 3.1% for the year 2022-30. The main growth drivers of the Canadian clinical diagnostics market are growing awareness about early disease detection and the benefits of early treatment. Further, the increasing investments by the government in diagnostic services are responsible for the market growth.To get a detailed report, contact us at - info@insights10.com
Canada Clinical Diagnostics Market Sample Report 2022 to 2030Insights10
Canada's clinical diagnostics is expected to witness significant growth from $3.9 Bn in 2022 to $4.9 Bn in 2030 with a CAGR of 3.1% for the year 2022-30.
With the advent of advanced technologies like machine learning, artificial intelligence, and the Internet of things in Canada, the Canadian telemedicine market is expected to grow from $4.86 Bn in 2022 to $18.53 Bn in 2030 with a CAGR of 18.2% for the year 2022-2030. The market is segmented by products and services, end users, and delivery mode. To get a detailed report, contact us at - info@insights10.com
Canada Digital Health Market Analysis Sample ReportInsights10
The Canadian digital health market is projected to grow from $16.88 Bn in 2022 to $66.07 Bn in 2030 with a CAGR of 18.6% for the year 2022-2030. Many companies in Canada are entering into a digital pace focussed on providing accessibility, quality, and efficient treatments in Canada. The market is segmented by technology, end users and components. To get a detailed report, contact us at - info@insights10.com
Digital therapeutics market is expected to grow from US$ 4,226.94 million in 2021 to US$ 18,061.79 million by 2028; it is estimated to grow at a CAGR of 23.1% from 2021 to 2028
This report presents a strategic analysis of the Canada Dermatology
Prescription market and a forecast for its development in the medium
and long term. It provides a comprehensive overview of the market
value, dynamics, segmentation, characteristics, main players, trends and
insights, growth and demand drivers, challenges & future outlook, etc.
This is one of the most comprehensive reports about the Canada
Dermatology Prescription market, offering unmatched value, accuracy
and expert insights.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
The digital therapeutics market is expected to grow from US$ 4,226.94 million in 2021 to US$ 18,061.79 million by 2028; it is estimated to grow at a CAGR of 23.1% from 2021 to 2028.
Canada's dermatology prescription market is expected to grow from $459.7 Mn in 2022 to $927.4 Mn in 2030 with a CAGR of 9.2% for the year 2022-30. Rising incidences of dermatology disorders involving the skin, nails, hair, etc, and the demand for novel therapeutics for the treatment of dermatology disorders in Canada are major market drivers of the Canadian dermatology prescription market. To get a detailed report, contact us at - info@insights10.com
This report presents a strategic analysis of the Global Dermatology Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. To get a detailed report, contact us at - info@insights10.com
Digital Therapeutics has shown the potential to address the unmet needs of patients. The ability of the companies to leverage the Therapeutics to address these gaps, much faster product development timelines, rising awareness and steps taken by governments has been a major market drivers.
The market has made significant progress in the past decade by harnessing technology to supplement or potentially replace traditional medical practices and therapies.
Visit https://insights10.com/ for more healthcare industry insights.
Global Aesthetic Devices Market AnalysisInsights10
Global aesthetic device market size was accounted at around USD 11.2B in 2021 and is projected to reach USD XXBn by 2029, exhibiting a CAGR of around 10.5% during the forecast period
North America is expected to be the highest contributor to this market, with USD 4.1B in 2021, and is anticipated to reach XXBn by 2029, registering a CAGR of XX%
Increasing acceptance of minimally invasive and non-invasive aesthetic processes will escalate the growth of aesthetic device market
Non-invasive aesthetic treatment market is valued at USD 6.5B in 2021 and is projected to reach XXBn by 2029, expected to grow at a CAGR of XX% during forecast period
Global aesthetic devices market is anticipated to gain momentum from the rapid advancements in aesthetic device technologies
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us @ info@insights10.com
INDIA MEDICAL DEVICE REGULATORY LANDSCAPEInsights10
The Indian medical device regulatory landscape is constantly evolving. In recent years, the government has implemented several new regulations to improve the safety and quality of medical devices. This has created new challenges and opportunities for medical device manufacturers and importers. To get a detailed report, contact us at - info@insights10.com, visit - https://bit.ly/3T4fMvE
Promising New Cancer Drugs Jan 2024 by Insights10Insights10
Medtech Monday: Bullish Bets on Breakthroughs - Examining Cutting-Edge Trials and Investment Opportunities Attention all healthcare and biotech investors! Buckle up for a deep dive into the hottest clinical trials poised to shape the future of medicine in 2024 and beyond. To get a detailed report, contact us at - info@insights10.com, visit - https://bit.ly/3uGcvZW
Patient - First Health With Generative AIInsights10
Patient-First Health With Generative AI Learn about the groundbreaking potential of #GenerativeAI in patient engagement, including its three broad categories of use cases. Understand why this innovation is poised to revolutionize patient interaction with their health and the crucial steps stakeholders must take to bring it to fruition. Don't miss this essential read by Insights10 for anyone passionate about the intersection of AI and healthcare! To get a detailed report, contact us at - info@insights10.com, visit - https://bit.ly/42OOgWa
Vietnam In-Vitro Fertilization (IVF) Service Market AnalysisInsights10
This report presents a strategic analysis of Vietnam In Vitro Fertilisation (IVF) Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. To get a detailed report, contact us at - info@insights10.com
By 2030, it is anticipated that the Turkey nutrition and supplements market will reach a value of $6.08 Mn from $3.05 Mn in 2022, growing at a CAGR of 9% during 2022-2030. The nutritional supplements market in Turkey is primarily dominated by local players such as Form Labs, Hülya Şahin, and Solgar. To get a detailed report, contact us at - info@insights10.com
Spain Artificial Intelligence (AI) in Healthcare Market AnalysisInsights10
Spain's Artificial Intelligence (AI) In Healthcare Market is projected to grow from $0.13 Bn in 2022 to $2.49 Bn by 2030, registering a CAGR of 44.22% during the forecast period of 2022-2030. The market will be driven by the government's support and increasing industry collaborations. The market is segmented by healthcare components & by healthcare applications. Some of the major players include IBM Watson Health, Methinks & IOMED. To get a detailed report, contact us at - info@insights10.com
The Kenya home healthcare market was valued at $XX Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of XX% from 2022 to 2030 and will reach $XX Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies and the aging population. The market is segmented by indication and product. To get a detailed report, contact us at - info@insights10.com
Japan Nutritional Supplements Market Analysis.pdfInsights10
By 2030, it is anticipated that the Japan Nutrition and Supplements market will reach a value of $47.25 Bn from $23.71 Bn in 2022, growing at a CAGR of 9% during 2022-30. The market is primarily dominated by local players such as Otsuka Pharmaceutical, Taisho Pharmaceutical, Kikkoman Corporation, and Ajinomoto.To get a detailed report, contact us at - info@insights10.com
By 2030, it is anticipated that the Australian dermatology drugs market will reach a value of $516 Mn from $204 Mn in 2022, growing at a CAGR of 12.3% during 2022-2030. The market is primarily dominated by local players such as Faulding, Bioscience International, Aspen Pharmacare, and Alpha Pharm. The market is driven by an aging population, disparities in universal health coverage, and the launch of new and innovative drugs. To get a detailed report, contact us at - info@insights10.com
India 3D Printing Medical Devices Market AnalysisInsights10
India's 3D printing medical devices market size was valued at $54 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 17.8% from 2022 to 2030 and will reach $222 Mn in 2030. The market is segmented by component, application, technology, and end user. To get a detailed report, contact us at - info@insights10.com
Australia Nutritional Supplements Market AnalysisInsights10
By 2030, it is anticipated that the Australian nutrition and supplements market will reach a value of $9.81 Bn from $4.58 Bn in 2022, growing at a CAGR of 10% during 2022-30. The market is primarily dominated by local players such as Blackmores, BioMedicals, Nutralife, and Life-Space. To get a detailed report, contact us at - info@insights10.com
Hong Kong Pharmaceutical Market AnalysisInsights10
This report presents a strategic analysis of the Hong Kong Pharmaceutical Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. To get a detailed report, contact us at - info@insights10.com
Australia's healthcare diagnostic market is valued at $xx Bn in 2022 and would likely grow at a CAGR of 1.5% during 2022-2030. The Australia healthcare diagnostic market is segmented by product, end-user, and test type. The factors affecting its growth are prevalent chronic diseases, the rising geriatric population, insurance and reimbursement, and regulating bodies. To get a detailed report, contact us at - info@insights10.com
Mexico's connected healthcare market is projected to grow from $995.4 Mn in 2022 to $7469.23 Mn by 2030, registering a CAGR of 28.65% during the forecast period of 2022-30. The main factors driving the growth would be increasing technological adoption, the aging population, the rising prevalence of chronic diseases, and government support. To get a detailed report, contact us at - info@insights10.com
Global Clinical Trial Support Services Market AnalysisInsights10
This report presents a strategic analysis of the Global Clinical Trials Support Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. To get a detailed report, contact us at - info@insights10.com
South Africa Nutritional Supplements Market AnalysisInsights10
By 2030, it is anticipated that the South Africa Nutrition and Supplements market will reach a value of $xx Bn from $2.48 Bn Mn in 2022, growing at a CAGR of xx% during 2022-2030. The nutritional supplements market in South Africa is primarily dominated by local players such as Solal Technologies Aspen Pharmacare and Adcock Ingram. To get a detailed report, contact us at - info@insights10.com
Bulgaria Over The Counter (OTC) Pharmaceuticals Market AnalysisInsights10
Bulgaria's over-the-counter (OTC) pharmaceuticals market size was valued at $137.5 Mn in 2022 and is estimated to expand at a CAGR of 6.52% from 2022 to 2030 and will reach $227.9 Mn in 2030. OTC are non-prescription medications and are a vital component of the healthcare system, offering consumers accessible solutions for a wide range of common health issues. The market is segmented by product type and distribution channel. To get a detailed report, contact us at - info@insights10.com
By 2030, it is anticipated that the Japan Radiotherapy Market will reach a value of $711 Mn from $430 Mn in 2022, growing at a CAGR of 6.5% during 2022-30. The Radiotherapy Therapeutics Market in Japan is dominated by a few domestic players such as Hitachi, Mitsubishi Electric Corporation, and IHI Corporation. The radiotherapy market in Japan is segmented into different types, technologies, procedures, applications, and end-users.
To get a detailed report, contact us at - info@insights10.com
Generative AI Startup Scenario in India 2023Insights10
Let's see how Generative AI is revolutionizing Indian Healthcare. Imagine AI generating personalized treatment plans, predicting disease outbreaks, or even designing life-saving drugs. This isn't sci-fi, it's the thriving reality of India's Generative AI healthcare startups in 2023.
Startups like Tricuss, Niramai, PharmEasy, Qure.ai, and HealthifyMe are harnessing the power of generative models to tackle critical healthcare challenges.
Global Breast Cancer Therapeutics Market ArticleInsights10
With an increase in breast cancer cases worldwide and rising investments in the research and development projects for breast cancer treatment, the Global breast cancer therapeutics market is expected to grow from $18.2 Bn in 2022 to $48.04 Bn in 2030 with a CAGR of 12.9% for the year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. To get a detailed report, contact us at - info@insights10.com
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
1. Canada Cannabis for
GI Disease Market
Canada Cannabis for GI Disease Market – Segmented
by- by Application, Forecast 2020 till 2028
Sample Report
2. 2 Confidential
Sample
1. Canada Cannabis for GI Disease Market Overview……………………………………..…………………………..………………………………………………..05
a. Methodology and Scope
b. Market Overview
2. Market Growth Drivers………………………………………………………………………………………………………...............................................................14
a. Increase in Prevalence for Rise in Intake of Cannabis for GI Disease Market
b. Increase Awareness among Consumers Regarding Health Benefits of Cannabis
c. High Investment into Research and Development
3. Market Restraints………………………………………………………………………………………………..................................................................................17
a. Legal and Reimbursement Issues
b. Side effects of Cannabis
4. Cannabis for GI Disease Market Segmentation……………………………………………………………………………………………………………………….…18
a. By Application
i. Recreational
ii. Medical
b. By Product Type
i. Flowers
ii. Concentrates
iii.Others
Table of Content
3. 3 Confidential
Table of Content
Sample
5. Competitive Landscape……………………………...………………………………………………………………………….........................................................22
a. Key Players Revenue
b. Start-ups Leveraging Cannabis for GI Disease Market
6. Key Company Profiles…………………………….……………………………………………………………………………………………………………..…….....25
a. Canopy Growth Corporation overview, Product & Services, Strategies & Financials
b. CanniMed Limited , Product & Services, Strategies & Financials
c. Cannabis Sativa Inc., Product & Services, Strategies & Financials
d. Emerald Health Therapeutics Inc., Product & Services, Strategies & Financials
e. GB Sciences Inc., Product & Services, Strategies & Financials
f. Cara Therapeutics, Product & Services, Strategies & Financials
g. Pfizer Company, Product & Services, Strategies & Financials
h. MediPharm Labs Company, Product & Services, Strategies & Financials
7. R&D Initiatives by Major Companies…………………………………………………………………………………………………………………………………..42
a. R&D Expenditure by Major Companies
b. R&D Expenditure in Canada Cannabis Market
8. Access and Reimbursement Scenario…………………………………………………….…………………………………………………………………………..45
a. Key Market Access Considerations
b. General Reimbursement Environment
4. 4 Confidential
Table of Content
Sample
9. Future Development Growth ………………………………………………………………………….……………………….........................................................47
a. Key Players Revenue
b. Various Start-ups Leveraging Cannabis for GI Disease Market
10. Conclusion…………………………….…………………………………………..………………………………………………………………………………..……....50
6. 6 Confidential
Methodology and Scope
Research Methodology
▪ We implement a mix of primary and secondary research for our market estimate and forecast. The secondary research forms the initial
phase of our study where we conducted extensive data mining, referring to verified data sources such as independent studies,
government and regulatory published material, technical journals, trade magazines, and paid data sources. This forms the basis of our
estimates
▪ For forecasting, the following parameters were considered:
o Market drivers and restraints along with their current and expected impacts
o Technological scenario and expected developments
o End use industry trends and dynamics
o Trends in the consumer behavior
▪ We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the
expected market growth rate
▪ All our estimates and forecasts were verified through exhaustive primary research with the Key Industry Participants (KIPs)
7. 7 Confidential
Methodology and Scope (continued)
Research Scope and Assumption
▪ The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD Billion). The
market for each type has been provided on a regional basis for the above-mentioned forecast period
▪ The key industry dynamics, regulatory scenario, major technological trends, and application markets are evaluated to understand their
impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
▪ We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and
trends for various solutions, services, and end uses. The global market has been estimated by integrating the regional markets
▪ All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs)
▪ Inflation has not been accounted for in order to estimate and forecast the market
▪ Numbers may not add up due to rounding off
8. 8 Confidential
Methodology and Scope (continued)
List of Data Sources used in this Report
▪ Some of the secondary sources used for this report include but are not limited to:
o Canada government annual reports
o Federal Health Reforms Related to Cannabis for GI disease
o Funding Reports
o Annual Reports 2020 – For Key Market Players
o Government resources supporting Cannabis for GI disease
▪ Some of the primary sources used for this report include but are not limited to:
o Surveys through Questionnaires
o Interviews with Key Opinion Leaders
o Field surveys
9. 9 Confidential
Methodology and Scope (continued)
Key Benefit for Stakeholders from this Report
▪ The study provides an in-depth analysis of the Canada cannabis for GI disease treatment market with current trends and future
estimations to elucidate the imminent investment pockets
▪ Comprehensive analysis of factors that drive and restrict the market growth is provided.
▪ Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the
prevailing market opportunities
▪ Extensive analysis of the key segments of the industry helps understand the applications and technologies used globally
▪ Key market players and their strategies are provided to understand the competitive outlook of the market
11. 11 Confidential
Canada Cannabis for GI Disease Market Overview (Current and
Forecasted)
Canada Cannabis for GI Disease ($ CA Bn) (2020-2028)
▪ The Canada cannabis for GI Disease market accounted for $CA
2.6 Bn in 2020 and is expected to grow during the forecast period
▪ Medical cannabinoid products are widely used in Canada to treat
medical symptoms of all kinds, and gastrointestinal (GI) symptoms
are among the most cited reasons for use
▪ Cannabis is also widely used recreationally, and legalization of
recreational use has occurred in Canada. Cannabis can be
beneficial for individuals taking opioid medications for abdominal
pain
▪ Research shows that cannabis helps patients cut down on or
eliminate their need for opioids and provides treatment with fewer
side effects. With legalization of cannabis in Canada as of 2018,
we hope to see more research, dialogue, and deeper
understanding of how cannabis works in humans
2020 2021 2022 2023 2024 2025 2026 2027 2028
2.6
xx
Key Analysis
13. 13 Confidential
Market Growth Drivers and Restraints
Increased Prevalence for
rise in Intake of Cannabis
for GI disease
High Investment into
Research and
Development
Increased Awareness
among Consumers
regarding Health benefits
of Cannabis
Side effects of Cannabis
Legal & Reimbursement
Issues
Impact
Impact
Market
Drivers
Market
Restraints
14. 14 Confidential
Market Growth Drivers
1. Increased Prevalence for Rise in Intake of Cannabis for GI disease
Legalization of cannabis has allowed people to practice safe substance usage along with realizing its medicinal benefits,
which has led to a substantial increase in use of cannabis for GI Disease in Canada
Current research indicates that some conditions may be clinically improved by cannabis use. These include inflammatory
bowel disease, multiple sclerosis, neuropathic pain, nausea and vomiting caused by cancer or chemotherapy, pediatric
seizure disorders, and a wide variety of other illnesses
It seems to universally be effective at reducing abdominal pain. It can be especially useful for individuals taking opioid
medications for abdominal pain, as research shows that cannabis helps patients cut down on or eliminate their need for
opioids and provides a treatment with fewer side effects
15. 15 Confidential
Market Growth Drivers (continued)
2. Increased Awareness among Consumers Regarding Health benefits of Cannabis
According to 2020 Canadian Cannabis Survey, more than half of those who use cannabis choose to obtain it through a
legal source. 41% reported legal storefront as their usual source, an increase from 24% in 2019, whereas 13% reported
obtaining cannabis from a legal online source
Almost 8 in 10 Canadians feel they have access to trustworthy information to make informed decisions about their
cannabis use. An increase from 71% in 2019 to 77% in 2020. Information about the health risks associated with cannabis
use is widely available and reaching Canadians
The marijuana plant Cannabis sativa and its derivatives, cannabinoids, have grown increasingly popular as a potential
therapy for inflammatory bowel disease (IBD), and the awareness regarding the same has increased in Canada
16. 16 Confidential
Market Growth Drivers (continued)
3. High Investment into Research and Development
The Canadian Centre on Substance Use and Addiction (CCSA) is investing $1.8 million dollars in research on non-
therapeutic cannabis and the impacts of its legalization on public health and safety throughout the country
Through financial support from Health Canada, CCSA is funding 19 projects on subjects ranging from cannabis
legalization and mental health to a comparison of legal versus illicit cannabis sales
Content
Sample
17. 17 Confidential
Market Restraints
▪ Breathing problems: Marijuana smoke irritates the lungs,
and people who smoke marijuana frequently can have the
same breathing problems as those who smoke tobacco.
These problems include daily cough and phlegm, more
frequent lung illness, and a higher risk of lung infections
▪ Increased heart rate: Marijuana raises heart rate for up to 3
hours after smoking. This effect may increase the chance of
heart attack
▪ Content
▪ Content
▪ The Task Force recommends that the federal government set
a national minimum age of purchase of 18, acknowledging the
right of provinces and territories to harmonize it with their
minimum age of purchase of alcohol
▪ There are various regulations owing to the misuse of cannabis
in Canadian Market
▪ Content
▪ Content
Sample Sample
Legal & Reimbursement Issues Side Effects of Cannabis
20. 20 Confidential
Market Segmentation: By Application
▪ By application, the market is segmented into medical and
recreational
▪ Recreational segment dominated the market owing to the high
demand and consumption of cannabis for recreational
purposes
▪ Thus, the legalization of recreational applications has huge
potential to translate into a large market
▪ Content
▪ Content
Recreational Medical
Sample
Market Share, by Application Key Analysis
21. 21 Confidential
Market Segmentation: By Product Type
▪ Based on product type, concentrates is the fastest-growing
segment in the market, but flowers have the highest growth
▪ The growth of this segment is majorly attributed to its ease in
usage and its versatility in the method of delivery
▪ These concentrates are offered in the form of dabbing,
ingestible oils, and tinctures. They also offer cleaner and
smoother hits than the flower
▪ Content
▪ Content
Flowers Concentrates Others
Sample
Market Share, by Product Type Key Analysis
24. 24 Confidential
Start ups Leveraging Cannabis for GI Disease Market
Ample Organics is an information technology company that offers enterprise seed-to-sale inventory
software for the cannabis industry. The company was founded in 2014 and based in Toronto,
Ontario
Canopy Health Innovations, a bio-pharmaceutical company focused on developing innovative
cannabis-based related products. The goal is to develop a range of effective formulations and
delivery mechanisms that serve patients worldwide
Lobo Genetics is a healthcare technology start up company with the goal of helping you better
understand your response to cannabis through genetics
Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. It also
produces and sells indoor cultivation systems and hemp related food products
HEXO Corp is a consumer packaged goods cannabis company that creates and distributes prize-
winning products to serve the global
Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult
recreational consumers in Canada, as well as developing international business partnerships
to extend the Company’s global footprint
26. 26 Confidential
Canopy Growth Corporation
▪ Canopy Growth is a diversified cannabis and cannabinoid-
based consumer product company, driven by a passion to
improve lives, end prohibition, and strengthen communities by
unleashing the full potential of cannabis
▪ Leveraging consumer insights and innovation, it offer product
varieties in high-quality dried flower, oil, soft gel capsule,
infused beverage, edible, and topical formats, as well as
vaporizer devices by Canopy Growth and industry-leader
Storz & Bickel
▪ Canopy Growth has acquired 17 organizations. Their most
recent acquisition was Supreme Cannabis on Apr 8,
2021. They acquired Supreme Cannabis for $435M
Company Name: Canopy Growth
Corporation
Year of Establishment: 2014
Headquarter: Ontario, Canada
Revenue: $300 million
Website: https://www.canopygrowth.com/
Company Profile
27. 27 Confidential
Canopy Growth Corporation
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020
28. 28 Confidential
Cannabis Sativa Inc.
▪ Cannabis Sativa, Inc. develops and promotes natural cannabis
products. The Company is engaged in the research,
development and licensing of natural cannabis products,
including cannabis formulas, edibles, topicals, strains, recipes
and delivery systems
▪ The Company plans to develop, produce and market products
through joint ventures with companies licensed under state
regulations applicable to cannabis businesses
▪ It holds the license for a medicinal cannabis strain called NZT,
a cannabis lozenge delivery methodology, and a cannabis
trauma cream formula. The Company is also developing a
third strain of cannabis plant named CT22
Company Name: Cannabis Sativa Inc.
Year of Establishment: 2005
Headquarter: United States
Revenue: $2.04 million
Website: http://cannabissativainc.com/
Company Profile
29. 29 Confidential
Cannabis Sativa Inc.
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020
31. 31 Confidential
CanniMed Limited
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020
32. 32 Confidential
Emerald Health Therapeutics Inc.
Company Name:
Year of Establishment:
Headquarter:
Revenue:
Website:
Sample
Company Profile
Sample
33. 33 Confidential
Emerald Health Therapeutics Inc.
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020
34. 34 Confidential
G B Sciences Inc.
Company Name:
Year of Establishment:
Headquarter:
Revenue:
Website:
Company Profile
Sample
Sample
35. 35 Confidential
G B Sciences Inc.
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020
37. 37 Confidential
Cara Therapeutics
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020
39. 39 Confidential
Pfizer
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020
41. 41 Confidential
MediPharm Labs
2020 2024 2028
Analysis
▪ The company is profiled for the financial year ended, 2028
▪ Content
Sample
Revenues ($ Mn), 2020-2028 Breakdown of Net Sales (%) by segment, 2020
43. 43 Confidential
R&D Expenditure By Major Companies
Canada is well-positioned to lead the world in advancing R&D in
the cannabis sector. With the spread of legalization, R&D in the
cannabis sector can now be fully realized, placing Canada’s
cannabis industry in an excellent position to harness the power
of clinical data to further the evidence-based case
Canopy Growth has established an R&D arm, Canopy Health
Innovations, to its suite of subsidiaries with the intent of filing
new drug applications
Sample
Cannabis Sativa Inc. Canopy Growth Corporation
Emerald Health Therapeutics Inc CannMed Limited
GB Sciences Inc. Cara Therapeutics
Pfizer MediPharm Labs
Sample
Key Insights R&D Expenditure of Major Companies ($Bn), 2020
44. 44 Confidential
R&D in Canada Cannabis Market
R&D may be helpful in many cases, such as:
▪ Advance the understanding of the chemicals already present in different strains of cannabis and the therapeutic properties of cannabis
for health conditions, as well as the potential effects of accumulated exposure over time
▪ Optimise production processes to improve yields and minimise costs
▪ Create new and innovative products that will better meet consumers’ needs and develop safer dosing methods for more precise ingestion
of cannabis
▪ Sufficient research may give more confidence to physicians on cannabis safety and efficacy and impact the number of prescriptions that
patients receive
▪ Cannabis innovation may drive new approaches in the extraction processes, allowing a higher and more precise yield of raw material
▪ Research into cannabis benefits for other health conditions yet to be explored
▪ To gain market share with innovative cannabis products
▪ To be recognized and accepted by regulatory agencies such as Health Canada, the Food and Drug Administration, and the European
Medicines Agency
Sample
46. 46 Confidential
The Task Force recommends that the federal
government set a national minimum age of
purchase of 18, acknowledging the right of
provinces and territories to harmonize it with their
minimum age of purchase of alcohol
Access and Reimbursement Scenario
▪ Federal government use licensing and production controls to encourage a diverse, competitive market that also includes small
producers
▪ Implements a seed-to-sale tracking system to prevent diversion and enable product recalls
▪ Promotes environmental stewardship by implementing measures such as permitting outdoor production, with appropriate security
measures
▪ Content
▪ Content
General Reimbursement Environment
Key Market Access Considerations
1
Apply comprehensive restrictions to the
advertising and promotion of cannabis and related
merchandise by any means, including
sponsorship, endorsements and branding
2
Sample
48. 48 Confidential
Key Industry Developments: Offerings and Approvals
In December 2020, Aphria Inc. and Tilray, Inc. (Canada) entered into a definitive agreement to combine their businesses and
create the world’s largest cannabis company. The Combined Company, supported by low-cost cultivation, processing, and
manufacturing facilities, would have a complete portfolio of branded Cannabis 2.0 products in Canada)
In November 2020, Canopy Growth Corporation launched a new line of CBD-infused beverages named Quatreau. These are
naturally flavored sparkling waters, which are available in both CBD-only and balanced (CBD + THC) offerings. The company
introduced this line of products as an alternative to sugary, caffeinated beverages or even alcohol
Content
Content
49. 49 Confidential
Ongoing Clinical Trials
Dr. Burnham is a primary investigator in the first study in Canada to examine the impact of cannabis oil on the reduction of
convulsive seizures in adults. This phase III, double-blind, randomized, placebo-controlled trial, which looks at CBD
(cannabidiol), plus THC (tetrahydrocannabinol) – at a ratio of 16:1, will take about two years to complete
Avicanna Inc. is waiting for Health Canada to approve a clinical trial application at a top Toronto-based hospital, for a phase
II/III study of a cannabidiol cream to alleviate the painful blisters caused by epidermolysis bullosa [Butterfly Disease] in children
Content
Content
51. 51 Confidential
Conclusion
Strong Demand
Increased Prevalence of
cannabis is expected to
increase exponentially due to
increase in awareness about
cannabis and its use
Challenges
There is a lack of acceptance of
cannabis as a medical therapeutic
because of there is an assumption
that cannabis is to be consumed
only via smoking
Availability of Funding
CCSA is investing $1.8 million
dollars in research on non-
therapeutic cannabis for
development of new products
Advancement in Treatment
Advancement in treatment of GI
Diseases have been trending
during this pandemic situation
due to its severity and relation
with COVID-19
Growing Start-ups
Canada has witnessed
development in startups in
diabetes market domain and is
leading to enormous growth